Immune Checkpoint Inhibitor-Associated Immune-Mediated Nephropathy: A Real-World Pharmacovigilance Study.

J Clin Med · 2026 · PMC13207501 · PMID 42194777

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In our pharmacovigilance analysis, ICI combination therapy and ICI combined with targeted therapy demonstrated numerically higher reporting frequencies of immune-mediated nephropathy compared to ICI monotherapy, although these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.